The cost-effectiveness analysis of KEYNOTE-042 displayed that ICERs of $136228.82, $160625.98, and $179530.17 per QALY for advanced NSCLC patients with PD-L1 ≥50, ≥20, and ≥1%, respectively, and that pembrolizumab monotherapy was cost-effective in patients with PD-L1 ≥ 50% but not in the ≥20 and 1% populations at a WTP threshold of $150,000 per QALY in the US (49). The gene discussed is CD274; the disease is non-small cell lung carcinoma.